Interestingly, Okada et al. demonstrated that downregulation of EGFR in tumor tissue after treatment with anti-EGFR antibodies was significantly correlated with therapeutic response in patients with colorectal cancer [39]. The gene discussed is EGFR; the disease is neoplasm.